Cerebral
venous thrombosis (CVT), a rare thrombotic event that can cause serious
neurologic deficits, has been reported after some
ChAdOx1 nCoV-19 vaccinations against
coronavirus disease 2019 (COVID-19). However, there are few reports of associations between
COVID-19 mRNA vaccination and CVT. We retrospectively analyzed CVT occurrence, time of onset after vaccination, outcomes (recovered/not recovered), and death after
COVID-19 vaccination from
adverse drug reactions (ADR) reports in VigiBase. A disproportionality analysis was performed regarding
COVID-19 mRNA vaccines (
BNT162b2 and
mRNA-1273) and the
ChAdOx1 nCoV-19 vaccine. We identified 756 (0.07%) CVT cases (620 (0.05%) after
BNT162b2 and 136 (0.01%) after
mRNA-1273) of 1,154,023
mRNA vaccine-related ADRs. Significant positive safety signals were noted for
COVID-19 mRNA vaccines (95% lower end of information component = 1.56; reporting odds ratio with 95% confidence interval (CI) = 3.27). The median days to CVT onset differed significantly between the
BNT162b2 and
ChAdOx1 nCoV-19 vaccines (12 (interquartile range, 3−22) and 11 (interquartile range, 7−16), respectively; p = 0.02). Fewer CVT patients died after receiving
mRNA vaccines than after receiving the
ChAdOx1 nCoV-19 vaccine (odds ratio, 0.32; 95% CI, 0.22−0.45; p < 0.001). We noted a potential safety signal for CVT occurrence after
COVID-19 mRNA vaccination. Therefore, awareness about the risk of CVT, even after
COVID-19 mRNA vaccination, is necessary.